患者的心声：测量患者对皮肌炎症状的生活体验。

IF 3.6 2区医学 Q2 RHEUMATOLOGY Journal of Rheumatology Pub Date : 2024-11-01 DOI:10.3899/jrheum.2024-0951

Kaveh Ardalan, Lisa G Rider

{"title":"患者的心声：测量患者对皮肌炎症状的生活体验。","authors":"Kaveh Ardalan, Lisa G Rider","doi":"10.3899/jrheum.2024-0951","DOIUrl":null,"url":null,"abstract":"The development and validation of measures of disease activity, damage, and health-related quality of life (HRQOL) over the past 30 years has been fundamental in advancing research and care for patients with adult and juvenile idiopathic inflammatory myopathies (IIMs).1 These efforts have resulted in the development of core set measures of disease activity and damage for myositis, and the American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR)-endorsed Myositis Response Criteria, which have been successfully implemented in IIM clinical trials and which recently facilitated the US Food and Drug Administration licensure of intravenous immunoglobulin for dermatomyositis (DM).2-5.","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":null,"pages":null},"PeriodicalIF":3.6000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Ringing in the Patient Voice: Measuring Patients' Lived Experience of Dermatomyositis Symptoms.\",\"authors\":\"Kaveh Ardalan, Lisa G Rider\",\"doi\":\"10.3899/jrheum.2024-0951\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The development and validation of measures of disease activity, damage, and health-related quality of life (HRQOL) over the past 30 years has been fundamental in advancing research and care for patients with adult and juvenile idiopathic inflammatory myopathies (IIMs).1 These efforts have resulted in the development of core set measures of disease activity and damage for myositis, and the American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR)-endorsed Myositis Response Criteria, which have been successfully implemented in IIM clinical trials and which recently facilitated the US Food and Drug Administration licensure of intravenous immunoglobulin for dermatomyositis (DM).2-5.\",\"PeriodicalId\":50064,\"journal\":{\"name\":\"Journal of Rheumatology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Rheumatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3899/jrheum.2024-0951\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3899/jrheum.2024-0951","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

在过去的 30 年中，疾病活动度、损伤和健康相关生活质量（HRQOL）测量方法的开发和验证对于推动成人和青少年特发性炎症性肌病（IIMs）患者的研究和治疗至关重要。1 这些努力促成了肌炎疾病活动度和损伤核心指标的制定，以及美国风湿病学会（ACR）/欧洲风湿病学协会联盟（EULAR）认可的肌炎反应标准（Myositis Response Criteria）的制定，该标准已成功应用于特发性炎症性肌病（IIM）的临床试验中，最近还促成了美国食品药品管理局对皮肌炎（DM）静脉注射免疫球蛋白的许可2-5。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Ringing in the Patient Voice: Measuring Patients' Lived Experience of Dermatomyositis Symptoms.

The development and validation of measures of disease activity, damage, and health-related quality of life (HRQOL) over the past 30 years has been fundamental in advancing research and care for patients with adult and juvenile idiopathic inflammatory myopathies (IIMs).¹ These efforts have resulted in the development of core set measures of disease activity and damage for myositis, and the American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR)-endorsed Myositis Response Criteria, which have been successfully implemented in IIM clinical trials and which recently facilitated the US Food and Drug Administration licensure of intravenous immunoglobulin for dermatomyositis (DM).^2-5.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Rheumatology 医学-风湿病学

CiteScore

6.50

自引率

5.10%

发文量

285

审稿时长

1 months

期刊介绍： The Journal of Rheumatology is a monthly international serial edited by Earl D. Silverman. The Journal features research articles on clinical subjects from scientists working in rheumatology and related fields, as well as proceedings of meetings as supplements to regular issues. Highlights of our 41 years serving Rheumatology include: groundbreaking and provocative editorials such as "Inverting the Pyramid," renowned Pediatric Rheumatology, proceedings of OMERACT and the Canadian Rheumatology Association, Cochrane Musculoskeletal Reviews, and supplements on emerging therapies.